Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML.
Ball B, Xiao W, Borthakur G, Nguyen LXT, Valerio M, Venkatachalam A, Marcucci G, Stein A, Thai DL, Cook D, Chan K, Persaud S, Levine R, Abdel-Wahab O, Ben-Neriah Y, Stein E. Ball B, et al. Res Sq [Preprint]. 2024 Oct 15:rs.3.rs-4954060. doi: 10.21203/rs.3.rs-4954060/v1. Res Sq. 2024. PMID: 39483885 Free PMC article. Preprint.
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Bewersdorf JP, et al. Leuk Lymphoma. 2023 Jan;64(1):188-196. doi: 10.1080/10428194.2022.2136952. Epub 2022 Oct 26. Leuk Lymphoma. 2023. PMID: 36287540 Free PMC article.
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.
Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Bewersdorf JP, et al. Among authors: ball b. Blood Adv. 2024 Sep 24;8(18):4845-4855. doi: 10.1182/bloodadvances.2024012858. Blood Adv. 2024. PMID: 38941537 Free PMC article.
Concurrent versus sequential or no triazole anti-fungal therapy in patients undergoing 7 + 3 plus midostaurin induction for FLT-3 acute myelogenous leukemia.
Ngo D, Tinajero J, Zhang J, Stein A, Marcucci G, Salhotra A, Pullarkat V, Sandhu KS, Ball BJ, Pourhassan H, Koller P. Ngo D, et al. Among authors: ball bj. J Oncol Pharm Pract. 2024 Aug 16:10781552241276547. doi: 10.1177/10781552241276547. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 39150342
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW, Nemirovsky D, Famulare CA, Farnoud N, Mohanty AS, Stone-Molloy ZS, Chervin J, Ball BJ, Epstein-Peterson ZD, Arcila ME, Stonestrom AJ, Dunbar A, Cai SF, Glass JL, Geyer MB, Rampal RK, Berman E, Abdel-Wahab OI, Stein EM, Tallman MS, Levine RL, Goldberg AD, Papaemmanuil E, Zhang Y, Roshal M, Derkach A, Xiao W. McCarter JGW, et al. Among authors: ball bj. Blood Adv. 2023 Sep 12;7(17):5000-5013. doi: 10.1182/bloodadvances.2023009675. Blood Adv. 2023. PMID: 37142255 Free PMC article.
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg A, Stein E, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Bewersdorf JP, et al. Among authors: ball b. Am J Hematol. 2024 Aug;99(8):1640-1643. doi: 10.1002/ajh.27366. Epub 2024 May 15. Am J Hematol. 2024. PMID: 38751104 No abstract available.
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Aldoss I, et al. Among authors: ball b. Am J Hematol. 2023 Jun;98(6):848-856. doi: 10.1002/ajh.26908. Epub 2023 Mar 16. Am J Hematol. 2023. PMID: 36880203 Free article.
High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.
Pourhassan H, Yang D, Afkhami M, Pillai R, Ball B, Al Malki M, Salhotra A, Ali H, Artz A, Curtin P, Armenian S, Stein A, Forman SJ, Marcucci G, Pullarkat V, Nakamura R, Aldoss I. Pourhassan H, et al. Among authors: ball b. Am J Hematol. 2022 May;97(5):E171-E173. doi: 10.1002/ajh.26490. Epub 2022 Feb 11. Am J Hematol. 2022. PMID: 35132678 Free article. No abstract available.
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
Ball BJ, Arslan S, Koller P, Ngo D, Afkhami M, Salhotra A, Al-Malki M, Aribi A, Ali H, Sandhu K, Otoukesh S, Amanam I, Pourhassan H, Artz A, Curtin P, Stein A, Nakamura R, Marcucci G, Smith E, Pullarkat V, Aldoss I. Ball BJ, et al. Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10. Leuk Lymphoma. 2022. PMID: 36089918 No abstract available.
459 results